Precigen, Inc. (NASDAQ:PGEN) Receives $7.00 Consensus Price Target from Brokerages

Precigen, Inc. (NASDAQ:PGEN) has earned an average recommendation of “Moderate Buy” from the five research firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $7.00.

Separately, HC Wainwright reissued a “buy” rating and set a $4.00 target price on shares of Precigen in a research note on Friday, November 15th.

Precigen Trading Up 20.0 %

Shares of Precigen stock opened at $1.12 on Thursday. Precigen has a 52 week low of $0.65 and a 52 week high of $1.93. The company’s 50-day moving average price is $0.84 and its two-hundred day moving average price is $1.10. The stock has a market cap of $328.01 million, a PE ratio of -2.04 and a beta of 1.71.

Institutional Trading of Precigen

Several large investors have recently added to or reduced their stakes in PGEN. Iridian Asset Management LLC CT raised its holdings in shares of Precigen by 82.5% during the third quarter. Iridian Asset Management LLC CT now owns 3,775,960 shares of the biotechnology company’s stock worth $3,576,000 after acquiring an additional 1,706,815 shares in the last quarter. State Street Corp lifted its holdings in shares of Precigen by 1.0% during the 3rd quarter. State Street Corp now owns 2,872,064 shares of the biotechnology company’s stock valued at $2,720,000 after buying an additional 29,253 shares during the last quarter. Stifel Financial Corp lifted its holdings in shares of Precigen by 94.9% during the 3rd quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 15,680 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Precigen by 11.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,222,850 shares of the biotechnology company’s stock valued at $1,158,000 after buying an additional 127,467 shares in the last quarter. Finally, FMR LLC increased its holdings in Precigen by 26.4% in the third quarter. FMR LLC now owns 345,204 shares of the biotechnology company’s stock worth $327,000 after buying an additional 72,033 shares during the last quarter. 33.51% of the stock is owned by institutional investors and hedge funds.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.